Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06074510 · ClinicalTrials.gov registry record · Phase 4

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

A Phase 4 study of Prostate Cancer, sponsored by Lantheus Medical Imaging.

Active
Registry status
Phase 4
Development phase
274
Enrollment target
14
Study locations

NCT06074510 is a Phase 4 study of Prostate Cancer that is active but no longer recruiting, run by Lantheus Medical Imaging. The registered enrollment target is 274 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (55% lower). The trial reports 14 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06074510, a Phase 4 study of Prostate Cancer, is active but no longer recruiting, sponsored by Lantheus Medical Imaging.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
274 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. Participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular PSA blood draws if ordered by doctors for up to 12 months after the study scan.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Piflufolastat F 18 Intravenous Solution [PYLARIFY]

Study Locations (14)

California

  • Hoag Cancer Center - Irvine
  • Tower Urology - Los Angeles
  • University of California San Francisco - San Francisco

Michigan

  • Karmanos Cancer Institute Wayne State University - Detroit
  • BAMF Health - Grand Rapids

Alabama

  • University of Alabama at Birmingham - Birmingham

Georgia

  • Emory University - Atlanta

Iowa

  • University of Iowa Health Care - Iowa City

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2024-02-08
Est. Completion 2026-09
Phase Phase 4

Sponsor

Lantheus Medical Imaging

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06074510

The ClinicalTrials.gov registry entry for NCT06074510 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Piflufolastat F 18 Intravenous Solution [PYLARIFY] is the first listed.

NCT06074510 reports 14 study locations spanning 11 distinct geographic areas - top geographies include California, Michigan, Alabama.

Frequently Asked Questions

What is clinical trial NCT06074510 about?

NCT06074510 is a clinical study titled "PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer". The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. Participants will receive a single dose of PYLARIFY ...

What is the current status of trial NCT06074510?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 274 participants. The study started on 2024-02-08. Estimated completion is 2026-09.

What conditions does trial NCT06074510 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06074510?

The interventions under investigation include: Piflufolastat F 18 Intravenous Solution [PYLARIFY] (DRUG).

Who is sponsoring clinical trial NCT06074510?

This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06074510 being conducted?

This trial has 14 study locations across Alabama, California, Georgia, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.